|
1
|
Li HX, Meng QP, Liu W, Li YG, Zhang HM,
Bao FC, Song LL and Li HJ: IMPDH2 mediate radioresistance and
chemoresistance in osteosarcoma cells. Eur Rev Med Pharmacol Sci.
18:3038–3044. 2014.PubMed/NCBI
|
|
2
|
Huh WW, Holsinger FC, Levy A, Palla FS and
Anderson PM: Osteosarcoma of the jaw in children and young adults.
Head Neck. 34:981–984. 2012. View Article : Google Scholar
|
|
3
|
Scholten DJ II, Timmer CM, Peacock JD,
Pelle DW, Williams BO and Steensma MR: Down regulation of Wnt
signaling mitigates hypoxia-induced chemoresistance in human
osteosarcoma cells. PLoS One. 9:e1114312014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mirabello L, Troisi RJ and Savage SA:
International osteo-sarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
6
|
Shang HS, Chang JB, Lin JH, Lin JP, Hsu
SC, Liu CM, Liu JY, Wu PP, Lu HF, Au MK, et al: Deguelin inhibits
the migration and invasion of U-2 OS human osteosarcoma cells via
the inhibition of matrix metalloproteinase-2/-9 in vitro.
Molecules. 19:16588–16608. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuijjer ML, Hogendoorn PC and
Cleton-Jansen AM: Genome-wide analyses on high-grade osteosarcoma:
Making sense of a genomically most unstable tumor. Int J Cancer.
133:2512–2521. 2013.PubMed/NCBI
|
|
8
|
Anninga JK, Gelderblom H, Fiocco M, Kroep
JR, Taminiau AH, Hogendoorn PC and Egeler RM: Chemotherapeutic
adjuvant treatment for osteosarcoma: Where do we stand? Eur J
Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zuo X, Qin Y, Zhang X, Ning Q, Shao S, Luo
M, Yuan N, Huang S and Zhao X: Breast cancer cells are arrested at
different phases of the cell cycle following the re-expression of
ARHI. Oncol Rep. 31:2358–2364. 2014.PubMed/NCBI
|
|
10
|
Li Y, Liu M, Zhang Y, Han C, You J, Yang
J, Cao C and Jiao S: Effects of ARHI on breast cancer cell
biological behavior regulated by microRNA-221. Tumour Biol.
34:3545–3554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fu Y, Chen J, Pang B, Li C, Zhao J and
Shen K: EZH2-induced H3K27me3 is associated with epigenetic
repression of the ARHI tumor-suppressor gene in ovarian cancer.
Cell Biochem Biophys. 71:105–112. 2015. View Article : Google Scholar
|
|
12
|
Li J, Cui G, Sun L, Wang SJ, Tian S, Guan
Z, Fan WS, Yan ZF, Yang YZ, You YQ, et al: ARHI overexpression
induces epithelial ovarian cancer cell apoptosis and excessive
autophagy. Int J Gynecol Cancer. 24:437–443. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang J, Lin Y, Li L, Qing D, Teng XM,
Zhang YL, Hu X, Hu Y, Yang P and Han ZG: ARHI, as a novel
suppressor of cell growth and downregulated in human hepatocellular
carcinoma, could contribute to hepatocarcinogenesis. Mol Carcinog.
48:130–140. 2009. View
Article : Google Scholar
|
|
14
|
Wu X, Liang L, Dong L, Yu Z and Fu X:
Effect of ARHI on lung cancer cell proliferation, apoptosis and
invasion in vitro. Mol Biol Rep. 40:2671–2678. 2013. View Article : Google Scholar
|
|
15
|
Chen J, Shi S, Yang W and Chen C:
Over-expression of ARHI decreases tumor growth, migration, and
invasion in human glioma. Med Oncol. 31:8462014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ria R, Todoerti K, Berardi S, Coluccia AM,
De Luisi A, Mattioli M, Ronchetti D, Morabito F, Guarini A,
Petrucci MT, et al: Gene expression profiling of bone marrow
endothelial cells in patients with multiple myeloma. Clin Cancer
Res. 15:5369–5378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Badgwell DB, Lu Z, Le K, Gao F, Yang M,
Suh GK, Bao JJ, Das P, Andreeff M, Chen W, et al: The
tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell
migration through inhibition of the Stat3 and FAK/Rho signaling
pathways. Oncogene. 31:68–79. 2012. View Article : Google Scholar
|
|
18
|
Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y,
Cuevas B, Kuo WL, Gray JW, Siciliano M, et al: NOEY2 (ARHI), an
imprinted putative tumor suppressor gene in ovarian and breast
carcinomas. Proc Natl Acad Sci USA. 96:214–219. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Prager GW, Poettler M, Unseld M and
Zielinski CC: Angiogenesis in cancer: anti-VEGF escape mechanisms.
Transl Lung Cancer Res. 1:14–25. 2011.
|
|
20
|
Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan
J, Lu Z, Bast RC Jr, Feng Y and Yu Y: Re-expression of ARHI
(DIRAS3) induces autophagy in breast cancer cells and enhances the
inhibitory effect of paclitaxel. BMC Cancer. 11:222011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Méndez M, Custodio A and Provencio M: New
molecular targeted therapies for advanced non-small-cell lung
cancer. J Thorac Dis. 3:30–56. 2011.
|
|
22
|
Waltering KK, Helenius MA, Sahu B, Manni
V, Linja MJ, Jänne OA and Visakorpi T: Increased expression of
androgen receptor sensitizes prostate cancer cells to low levels of
androgens. Cancer Res. 69:8141–8149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin D, Cui F, Bu Q and Yan C: The
expression and clinical significance of GTP-binding RAS-like 3
(ARHI) and microRNA 221 and 222 in prostate cancer. J Int Med Res.
39:1870–1875. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen MY, Liao WS, Lu Z, Bornmann WG,
Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA and Bast RC
Jr: Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit
growth of ovarian cancer cell lines and xenografts while inducing
expression of imprinted tumor suppressor genes, apoptosis, G2/M
arrest, and autophagy. Cancer. 117:4424–4438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu X, Qian J, Yu Y, Yang H and Li J:
Expression of the tumor suppressor ARHI inhibits the growth of
pancreatic cancer cells by inducing G1 cell cycle arrest. Oncol
Rep. 22:635–640. 2009.PubMed/NCBI
|
|
26
|
Janssen EA, Øvestad IT, Skaland I, Søiland
H, Gudlaugsson E, Kjellevold KH, Nysted A, Søreide JA and Baak JP:
LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast
cancer. Cell Oncol. 31:335–343. 2009.PubMed/NCBI
|
|
27
|
Zhao X, Li J, Zhuo J and Cai L:
Reexpression of ARHI inhibits tumor growth and angiogenesis and
impairs the mTOR/VEGF pathway in hepatocellular carcinoma. Biochem
Biophys Res Commun. 403:417–421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Visser S and Yang X: Identification of
LATS transcriptional targets in HeLa cells using whole human genome
oligonucleotide microarray. Gene. 449:22–29. 2010. View Article : Google Scholar
|
|
29
|
Li L, Luo J, Wang B, Wang D, Xie X, Yuan
L, Guo J, Xi S, Gao J, Lin X, et al: Microrna-124 targets
flotillin-1 to regulate proliferation and migration in breast
cancer. Mol Cancer. 12:1632013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li L, Yuan L, Luo J, Gao J, Guo J and Xie
X: MiR-34a inhibits proliferation and migration of breast cancer
through down-regulation of Bcl-2 and SIRT1. Clin Exp Med.
13:109–117. 2013. View Article : Google Scholar
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
32
|
Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare
S, Kondo S, Kondo Y, Yu Y, Mills GB, et al: The tumor suppressor
gene ARHI regulates autophagy and tumor dormancy in human ovarian
cancer cells. J Clin Invest. 118:3917–3929. 2008.PubMed/NCBI
|
|
33
|
Jovicic A, Zaldivar Jolissaint JF, Moser
R, Silva Santos MF and Luthi-Carter R: MicroRNA-22 (miR-22)
overexpression is neuroprotective via general anti-apoptotic
effects and may also target specific Huntington's disease-related
mechanisms. PLoS One. 8:e542222013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou Y, Zhu LB, Peng AF, Wang TF, Long XH,
Gao S, Zhou RP and Liu ZL: LY294002 inhibits the malignant
phenotype of osteosarcoma cells by modulating the
phosphatidylinositol 3-kinase/Akt/fatty acid synthase signaling
pathway in vitro. Mol Med Rep. 11:1352–1357. 2015.
|
|
35
|
Zhang Y, Yang CQ, Gao Y, Wang C, Zhang CL
and Zhou XH: Knockdown of CXCR7 inhibits proliferation and invasion
of osteosarcoma cells through inhibition of the PI3K/Akt and
β-arrestin pathways. Oncol Rep. 32:965–972. 2014.PubMed/NCBI
|
|
36
|
Lu Z, Yang H, Sutton MN, Yang M, Clarke
CH, Liao WS and Bast RC Jr: ARHI (DIRAS3) induces autophagy in
ovarian cancer cells by downregulating the epidermal growth factor
receptor, inhibiting PI3K and Ras/MAP signaling and activating the
FOXo3a-mediated induction of Rab7. Cell Death Differ. 21:1275–1289.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao Y, Luo LH, Li S and Yang C: miR-17
inhibitor suppressed osteosarcoma tumor growth and metastasis via
increasing PTEN expression. Biochem Biophys Res Commun.
444:230–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Papadimitriou K, Ardavanis A and
Kountourakis P: Neoadjuvant therapy for locally advanced breast
cancer: Focus on chemotherapy and biological targeted treatments'
armamentarium. J Thorac Dis. 2:160–170. 2010.PubMed/NCBI
|
|
39
|
Bao J-J, Le X-F, Wang R-Y, Yuan J, Wang L,
Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, et al:
Reexpression of the tumor suppressor gene ARHI induces apoptosis in
ovarian and breast cancer cells through a caspase-independent
calpain-dependent pathway. Cancer Res. 62:7264–7272.
2002.PubMed/NCBI
|
|
40
|
Yu P, Ye L, Wang H, Du G, Zhang J, Zhang J
and Tian J: NSK-01105 inhibits proliferation and induces apoptosis
of prostate cancer cells by blocking the Raf/MEK/ERK and
PI3K/Akt/mTOR signal pathways. Tumour Biol. 15:152014.
|
